Meghana Korikani

Estimated sensitivity profiles of lung cancer specific uncommon BRAF mutants towards experimental and clinically approved kinase inhibitors.

J. Subramanian, R. Kancha, N. Amanchi, 2022, Toxicology and applied pharmacology.

Applications of promiscuity of FDA-approved kinase inhibitors in drug repositioning and toxicity.

R. Kancha, Sravani Akula, Meghana Korikani, 2023, Toxicology and applied pharmacology.